#United States #Philadelphia #Berger Montague #Investor Alert #RxSight

Legal Alert for RxSight Investors

In a recent development, the prominent law firm Berger Montague PC has alerted RxSight investors regarding a potential class action lawsuit. The firm is investigating possible violations of securities laws involving RxSight, Inc. (NASDAQ: RXST). The class period spans from November 7, 2024, to July 8, 2025, concerning investors who acquired securities of the company during this timeframe.

Overview of the Class Action

Investors who purchased or acquired RxSight stocks during the specified class period have until September 22, 2025, to apply for appointment as lead plaintiff of the class. This class action stems from allegations that the company misrepresented crucial operational challenges. Specifically, claims arose that RxSight experienced 'adoption challenges' and structural issues that led to decreased sales and product utilization, causing the company to overstate the demand for its innovative light-adjustable intraocular lenses (LALs).

RxSight is based in Aliso Viejo, California, and specializes in the development and production of LALs used within cataract surgery, incorporating its proprietary Light Delivery Device (LDD). According to the lawsuit, these previously undisclosed challenges have likely hindered the company’s ability to meet its financial forecasts for the fiscal year of 2025.

Recent Financial Struggles

On July 8, 2025, RxSight revealed a drastic drop in LDD sales and LAL utilization in their second-quarter results, prompting a revision of their revenue guidance for the entire year. The company's CEO, Ronald Kurtz, pointed to prevailing adoption challenges as a primary barrier contributing to disappointing sales performance. Following this public disclosure, RxSight's stock plummeted by 37%, closing at just $7.95 a share the day after.

The significant downturn reflects investor concerns around RxSight’s operational integrity and future growth. The firm was previously riding a wave of optimism regarding its innovative ophthalmic technologies, but these recent developments have raised alarms among investors.

How to Get Involved

If you have invested in RxSight during this timeframe and wish to understand your legal rights, you can contact Berger Montague to explore your options. The firm’s legal representatives, Andrew Abramowitz and Caitlin Adorni, are available to guide you through the processes of the class action lawsuit. Investors should act promptly as the deadline is approaching.

For more information, interested parties can reach out directly to Berger Montague at:

• - Andrew Abramowitz

- Phone: (215) 875-3015
- Email: [email protected]

• - Caitlin Adorni

- Phone: (267) 764-4865
- Email: [email protected]

About Berger Montague

Founded in 1970, Berger Montague has firmly established itself as a leader in securities class action litigation. With its headquarters located in Philadelphia, the firm also has offices across several other U.S. cities and in Canada. Over the past five decades, it has dedicated itself to representing both individual and institutional investors in various legal matters, ensuring their rights and interests are protected.

Given the unfolding circumstances around RxSight, investors are encouraged to stay informed and seek legal counsel to navigate these challenges effectively.